According to Zacks, “Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros’ most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. “
OMER has been the subject of a number of other reports. Wedbush reaffirmed an outperform rating and set a $47.00 target price on shares of Omeros in a report on Wednesday, February 8th. WBB Securities reissued a buy rating and issued a $75.00 price objective on shares of Omeros in a research note on Thursday, November 17th. Maxim Group reissued a buy rating on shares of Omeros in a research note on Wednesday, March 1st. Finally, FBR & Co reissued a buy rating on shares of Omeros in a research note on Thursday, March 2nd. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Omeros currently has an average rating of Buy and a consensus target price of $33.38.
Omeros (NASDAQ:OMER) opened at 11.75 on Wednesday. The company has a 50-day moving average of $11.05 and a 200-day moving average of $10.51. Omeros has a 12 month low of $7.20 and a 12 month high of $16.38. The stock’s market cap is $504.25 million.
Your IP Address:
Several institutional investors have recently modified their holdings of OMER. Bank of Montreal Can boosted its stake in Omeros by 20.2% in the third quarter. Bank of Montreal Can now owns 2,015,248 shares of the biopharmaceutical company’s stock valued at $22,490,000 after buying an additional 338,263 shares during the last quarter. Wedbush Securities Inc. increased its position in shares of Omeros by 8.6% in the third quarter. Wedbush Securities Inc. now owns 92,635 shares of the biopharmaceutical company’s stock valued at $1,034,000 after buying an additional 7,372 shares during the period. Ingalls & Snyder LLC increased its position in shares of Omeros by 15.2% in the third quarter. Ingalls & Snyder LLC now owns 5,085,949 shares of the biopharmaceutical company’s stock valued at $56,759,000 after buying an additional 671,370 shares during the period. Virtus ETF Advisers LLC increased its position in shares of Omeros by 14.4% in the third quarter. Virtus ETF Advisers LLC now owns 55,936 shares of the biopharmaceutical company’s stock valued at $624,000 after buying an additional 7,049 shares during the period. Finally, Tocqueville Asset Management L.P. increased its position in shares of Omeros by 0.4% in the third quarter. Tocqueville Asset Management L.P. now owns 959,744 shares of the biopharmaceutical company’s stock valued at $10,711,000 after buying an additional 3,741 shares during the period. Hedge funds and other institutional investors own 47.94% of the company’s stock.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/2024402/omeros-co-omer-lifted-to-hold-at-zacks-investment-research.html
Receive News & Ratings for Omeros Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Co. and related companies with MarketBeat.com's FREE daily email newsletter.